Recognition of neuroectodermal tumors by melanoma-specific cytotoxic T lymphocytes: evidence for antigen sharing by tumors derived from the neural crest

Peter Shamamian, Marie Mancini, Yutaka Kawakami, Nicholas P. Restifo, Steven A. Rosenberg, Suzanne L. Topalian

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Melanomas from different patients have been shown to express shared tumor antigens, which can be recognized in the context of the appropriate MHC class 1 molecules by cytolytic T cells. To determine if T-cell-defined melanoma antigens are expressed on other tumors of neuroectodermal origin, four melanoma-specific cytotoxic T lymphocyte (CTL) cultures derived from tumor-infiltrating lymphocytes (TIL) were tested for lysis of a panel of 23 HLA-A2+ neuroectodermal tumor cell lines of various histologies, including retinoblastoma (1), neuroblastoma (8), neuroepithelioma (6), astrocytoma (2), neuroglioma (1), and Ewing's sarcoma (5). Low expression of MHC class I and/or ICAM-1 molecules was found on 22 of 23 neuroectodermal tumor lines, and could be enhanced by treatment with interferon γ (IFNγ). Following IFNγ treatment, three Ewing's sarcoma lines were lysed by at least one melanoma TIL culture, and levels of lysis were comparable to melanoma lysis by these TIL. Lysis could be inhibited by monoclonal antibodies directed against MHC class I molecules and against CD3, indicating specific immune recognition of tumor-associated antigens. None of the other neuroectodermal tumors tested were lysed by TIL, but they could be lysed by non-MHC-restricted lymphokine-activated killer cells. This demonstration of immunological cross-reactivity between melanomas and Ewing's sarcomas, two tumors of distinct histological types with a common embryonic origin, has implications for the developmental nature of these CTL-defined tumor antigens. It also raises the possibility that specific antitumor immunotherapies, such as vaccines, may be reactive against more than one form of cancer.

Original languageEnglish (US)
Pages (from-to)73-83
Number of pages11
JournalCancer Immunology Immunotherapy
Volume39
Issue number2
DOIs
StatePublished - Mar 1994
Externally publishedYes

Fingerprint

Neuroectodermal Tumors
Cytotoxic T-Lymphocytes
Tumor-Infiltrating Lymphocytes
Melanoma
Ewing's Sarcoma
Antigens
Neoplasm Antigens
Interferons
Melanoma-Specific Antigens
T-Lymphocytes
HLA-A2 Antigen
Lymphokine-Activated Killer Cells
Retinoblastoma
Astrocytoma
Intercellular Adhesion Molecule-1
Tumor Cell Line
Neuroblastoma
Immunotherapy
Neoplasms
Histology

Keywords

  • Ewing's sarcoma
  • Melanoma
  • Neural crest
  • Tumor-infiltrating lymphocyte

ASJC Scopus subject areas

  • Oncology
  • Immunology
  • Cancer Research

Cite this

Recognition of neuroectodermal tumors by melanoma-specific cytotoxic T lymphocytes : evidence for antigen sharing by tumors derived from the neural crest. / Shamamian, Peter; Mancini, Marie; Kawakami, Yutaka; Restifo, Nicholas P.; Rosenberg, Steven A.; Topalian, Suzanne L.

In: Cancer Immunology Immunotherapy, Vol. 39, No. 2, 03.1994, p. 73-83.

Research output: Contribution to journalArticle

Shamamian, Peter ; Mancini, Marie ; Kawakami, Yutaka ; Restifo, Nicholas P. ; Rosenberg, Steven A. ; Topalian, Suzanne L. / Recognition of neuroectodermal tumors by melanoma-specific cytotoxic T lymphocytes : evidence for antigen sharing by tumors derived from the neural crest. In: Cancer Immunology Immunotherapy. 1994 ; Vol. 39, No. 2. pp. 73-83.
@article{60a4018970214b838517bd7015ae3824,
title = "Recognition of neuroectodermal tumors by melanoma-specific cytotoxic T lymphocytes: evidence for antigen sharing by tumors derived from the neural crest",
abstract = "Melanomas from different patients have been shown to express shared tumor antigens, which can be recognized in the context of the appropriate MHC class 1 molecules by cytolytic T cells. To determine if T-cell-defined melanoma antigens are expressed on other tumors of neuroectodermal origin, four melanoma-specific cytotoxic T lymphocyte (CTL) cultures derived from tumor-infiltrating lymphocytes (TIL) were tested for lysis of a panel of 23 HLA-A2+ neuroectodermal tumor cell lines of various histologies, including retinoblastoma (1), neuroblastoma (8), neuroepithelioma (6), astrocytoma (2), neuroglioma (1), and Ewing's sarcoma (5). Low expression of MHC class I and/or ICAM-1 molecules was found on 22 of 23 neuroectodermal tumor lines, and could be enhanced by treatment with interferon γ (IFNγ). Following IFNγ treatment, three Ewing's sarcoma lines were lysed by at least one melanoma TIL culture, and levels of lysis were comparable to melanoma lysis by these TIL. Lysis could be inhibited by monoclonal antibodies directed against MHC class I molecules and against CD3, indicating specific immune recognition of tumor-associated antigens. None of the other neuroectodermal tumors tested were lysed by TIL, but they could be lysed by non-MHC-restricted lymphokine-activated killer cells. This demonstration of immunological cross-reactivity between melanomas and Ewing's sarcomas, two tumors of distinct histological types with a common embryonic origin, has implications for the developmental nature of these CTL-defined tumor antigens. It also raises the possibility that specific antitumor immunotherapies, such as vaccines, may be reactive against more than one form of cancer.",
keywords = "Ewing's sarcoma, Melanoma, Neural crest, Tumor-infiltrating lymphocyte",
author = "Peter Shamamian and Marie Mancini and Yutaka Kawakami and Restifo, {Nicholas P.} and Rosenberg, {Steven A.} and Topalian, {Suzanne L.}",
year = "1994",
month = "3",
doi = "10.1007/BF01525312",
language = "English (US)",
volume = "39",
pages = "73--83",
journal = "Medical Oncology and Tumor Pharmacotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "2",

}

TY - JOUR

T1 - Recognition of neuroectodermal tumors by melanoma-specific cytotoxic T lymphocytes

T2 - evidence for antigen sharing by tumors derived from the neural crest

AU - Shamamian, Peter

AU - Mancini, Marie

AU - Kawakami, Yutaka

AU - Restifo, Nicholas P.

AU - Rosenberg, Steven A.

AU - Topalian, Suzanne L.

PY - 1994/3

Y1 - 1994/3

N2 - Melanomas from different patients have been shown to express shared tumor antigens, which can be recognized in the context of the appropriate MHC class 1 molecules by cytolytic T cells. To determine if T-cell-defined melanoma antigens are expressed on other tumors of neuroectodermal origin, four melanoma-specific cytotoxic T lymphocyte (CTL) cultures derived from tumor-infiltrating lymphocytes (TIL) were tested for lysis of a panel of 23 HLA-A2+ neuroectodermal tumor cell lines of various histologies, including retinoblastoma (1), neuroblastoma (8), neuroepithelioma (6), astrocytoma (2), neuroglioma (1), and Ewing's sarcoma (5). Low expression of MHC class I and/or ICAM-1 molecules was found on 22 of 23 neuroectodermal tumor lines, and could be enhanced by treatment with interferon γ (IFNγ). Following IFNγ treatment, three Ewing's sarcoma lines were lysed by at least one melanoma TIL culture, and levels of lysis were comparable to melanoma lysis by these TIL. Lysis could be inhibited by monoclonal antibodies directed against MHC class I molecules and against CD3, indicating specific immune recognition of tumor-associated antigens. None of the other neuroectodermal tumors tested were lysed by TIL, but they could be lysed by non-MHC-restricted lymphokine-activated killer cells. This demonstration of immunological cross-reactivity between melanomas and Ewing's sarcomas, two tumors of distinct histological types with a common embryonic origin, has implications for the developmental nature of these CTL-defined tumor antigens. It also raises the possibility that specific antitumor immunotherapies, such as vaccines, may be reactive against more than one form of cancer.

AB - Melanomas from different patients have been shown to express shared tumor antigens, which can be recognized in the context of the appropriate MHC class 1 molecules by cytolytic T cells. To determine if T-cell-defined melanoma antigens are expressed on other tumors of neuroectodermal origin, four melanoma-specific cytotoxic T lymphocyte (CTL) cultures derived from tumor-infiltrating lymphocytes (TIL) were tested for lysis of a panel of 23 HLA-A2+ neuroectodermal tumor cell lines of various histologies, including retinoblastoma (1), neuroblastoma (8), neuroepithelioma (6), astrocytoma (2), neuroglioma (1), and Ewing's sarcoma (5). Low expression of MHC class I and/or ICAM-1 molecules was found on 22 of 23 neuroectodermal tumor lines, and could be enhanced by treatment with interferon γ (IFNγ). Following IFNγ treatment, three Ewing's sarcoma lines were lysed by at least one melanoma TIL culture, and levels of lysis were comparable to melanoma lysis by these TIL. Lysis could be inhibited by monoclonal antibodies directed against MHC class I molecules and against CD3, indicating specific immune recognition of tumor-associated antigens. None of the other neuroectodermal tumors tested were lysed by TIL, but they could be lysed by non-MHC-restricted lymphokine-activated killer cells. This demonstration of immunological cross-reactivity between melanomas and Ewing's sarcomas, two tumors of distinct histological types with a common embryonic origin, has implications for the developmental nature of these CTL-defined tumor antigens. It also raises the possibility that specific antitumor immunotherapies, such as vaccines, may be reactive against more than one form of cancer.

KW - Ewing's sarcoma

KW - Melanoma

KW - Neural crest

KW - Tumor-infiltrating lymphocyte

UR - http://www.scopus.com/inward/record.url?scp=0028279757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028279757&partnerID=8YFLogxK

U2 - 10.1007/BF01525312

DO - 10.1007/BF01525312

M3 - Article

C2 - 7519127

AN - SCOPUS:0028279757

VL - 39

SP - 73

EP - 83

JO - Medical Oncology and Tumor Pharmacotherapy

JF - Medical Oncology and Tumor Pharmacotherapy

SN - 0340-7004

IS - 2

ER -